NCT00879619View on ClinicalTrials.gov

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

October 31, 2011

Study Completion Date

November 30, 2011

Conditions
Prostate CancerAdenocarcinoma of the ProstateRecurrent Prostate CancerStage I Prostate CancerStage III Prostate CancerStage IV Prostate Cancer
Interventions
DRUG

sunitinib malate

Given PO

DRUG

docetaxel

Given IV

DRUG

prednisone

Given PO

Trial Locations (1)

92868

Chao Comprehensive Cancer Center, Orange

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

John P. Fruehauf

OTHER